BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

56.65 (USD) • At close June 6, 2025
Bedrijfsnaam BioMarin Pharmaceutical Inc.
Symbool BMRN
Munteenheid USD
Prijs 56.65
Beurswaarde 10,864,110,400
Dividendpercentage 0%
52-weken bereik 52.93 - 94.85
Industrie Biotechnology
Sector Healthcare
CEO Mr. Jean-Jacques Bienaime M.B.A., MBA
Website https://www.biomarin.com

An error occurred while fetching data.

Over BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with

Vergelijkbare Aandelen

Viatris Inc. logo

Viatris Inc.

VTRS

8.71 USD

Insulet Corporation logo

Insulet Corporation

PODD

311.77 USD

Bio-Techne Corporation logo

Bio-Techne Corporation

TECH

48.69 USD

Alnylam Pharmaceuticals, Inc. logo

Alnylam Pharmaceuticals, Inc.

ALNY

300.83 USD

Incyte Corporation logo

Incyte Corporation

INCY

68.77 USD

Henry Schein, Inc. logo

Henry Schein, Inc.

HSIC

70.37 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)